How Nandrolone Phenylpropionate Affects HDL Cholesterol

Nandrolone phenylpropionate and nandrolone decanoate deliver identical nandrolone, so the lipid mechanism is shared:

1. Injectable, no first-pass hepatic loading: The ester is cleaved in tissue and nandrolone reaches the liver at systemic concentrations rather than as a portal bolus. Thompson (1989, PMID 2915439) established this as the dominant determinant of androgen lipid damage: oral stanozolol raised hepatic lipase activity 123%, while intramuscular testosterone produced a 25% rise that was not statistically significant.

2. Not 17-alpha-alkylated: No alkyl group forces the molecule to survive hepatic metabolism, so the sustained hepatocyte androgen signal that oral steroids produce is absent.

3. Modest hepatic lipase upregulation: Nandrolone does upregulate hepatic triglyceride lipase, which catabolises HDL particles, but the magnitude is far lower than with orals and is dose-dependent.

4. Weak aromatisation, and the practical consequence: Nandrolone aromatises poorly, so it contributes little oestradiol to restrain hepatic lipase. In practice this matters less than expected, because nandrolone is almost always run with a testosterone base that supplies the oestradiol. It matters a great deal if an aggressive aromatase inhibitor is in play.

5. Lipoprotein(a) falls: Sattler (2002, PMID 12388173) measured Lp(a) falling by roughly 7 mg/dL over 12 weeks, and Hartgens (2004, PMID 15155420) documented a fall from 103 to 65 U/L at 200 mg/week. Lp(a) is largely genetically determined and diet-resistant, so an androgen lowering it is genuinely notable, though its net weight against the HDL fall is unresolved.

What the ester changes: the phenylpropionate ester has a half-life of roughly 2 to 3 days versus 6 to 12 for decanoate. Steady state within about a week, clearance within days.

High-dose nandrolone for 12 weeks (Sattler 2002, PMID 12388173, 30 men, randomised):

• HDL cholesterol: -8.7 mg/dL (nandrolone alone) and -10.6 mg/dL (nandrolone plus resistance training), both p less than 0.001
• The HDL2b and HDL2a subfractions fell while HDL3a and HDL3b rose, an unfavourable shift in subfraction distribution
• Total cholesterol, LDL cholesterol and LDL phenotype: no significant change
• Lipoprotein(a): down roughly 7 mg/dL
• Most changes reverted to baseline within 2 months of stopping

At 100 mg/week (Kuipers 1991, PMID 1917227, double-blind, placebo-controlled):

• HDL fell 25 to 27%, virtually fully reversed 6 weeks after cessation

At 200 mg/week for 8 weeks (Hartgens 2004, PMID 15155420, randomised double-blind, placebo-controlled):

• No significant change in total cholesterol, triglycerides, HDL, HDL2, HDL3, apoA-I or apoB
• The conflict with Kuipers is real and unresolved; both trials were double-blind and placebo-controlled

Practical expectation at bodybuilding doses (300-600 mg/week):

• HDL falling 20 to 35%, more than the trial doses would suggest because bodybuilding doses exceed them.
• In a stack, the oral compounds will dominate the picture.

Timing with the short ester: steady state within a week, so lipid changes are established by week 3 to 4. Recovery starts within days of the last injection.

Baseline lipid panel before the cycle.

On cycle:

• Check at week 4. The short ester reaches steady state quickly, so this timing is meaningful rather than premature.
• Track HDL, the LDL to HDL ratio and non-HDL cholesterol.
• ApoB if available, particularly if an oral is also in the stack.

Attribution:

• Nandrolone alone showed no LDL effect in two randomised trials, so an elevated LDL on an NPP cycle points at an oral or at an over-suppressed oestradiol.
• HDL is where nandrolone genuinely acts, and a fall of 20 to 35% at bodybuilding doses is expected.

Consider measuring Lp(a) once: it is largely genetically fixed and diet-resistant, so knowing your number has lasting value, and nandrolone lowering it is one of the few androgen effects on the lipid panel pointing the right way.

Post-cycle: Recheck at 6 to 8 weeks. The short ester means recovery starts sooner than with decanoate, where Hartgens found lipid changes still not back to baseline 6 weeks after cessation.

Do not over-suppress oestradiol: Nandrolone aromatises weakly, so the oestradiol on an NPP and testosterone cycle comes almost entirely from the testosterone, and it is the main restraint on hepatic lipase in the protocol. An aggressive aromatase inhibitor removes it.

Drop the oral before dropping the nandrolone: If lipids are the reason for a protocol change, an oral 17-alpha-alkylated compound is a far larger lever. Stanozolol suppressed HDL 33% at 6 mg/day in a controlled trial.

Cardiovascular exercise: 30 to 45 minutes, 4 to 5 times per week. It is the most effective HDL intervention available. Sattler's trial found the training group gained 5.2 angstroms of LDL particle size, a favourable shift the nandrolone-alone group did not show.

Supplements, honestly ranked:

• Omega-3 at 3 to 4 g/day EPA and DHA: effective for triglycerides, minimal for HDL
• Citrus bergamot 500 to 1000 mg/day: modest human evidence, none in androgen users

Ester advantage: If HDL crashes or another side effect appears, NPP clears within days. Decanoate does not, and Hartgens found lipid changes still unrecovered 6 weeks after stopping it.

Further reading: Cholesterol supplements on cycle, ranked by evidence